Photo of: Paul Chaplin

Dr. Paul Chaplin

View Title...

Bavarian Nordic
Paul's profile was created using:
Sort By:

1-10 of 12 online sources for Paul Chaplin

  • View Online Source
    pubs.acs.org/cen/coverstory/86/8638cover.html - [Cached Version]
    Published on: 9/22/2008    Last Visited: 9/23/2008  

    Danish vaccine developer Bavarian Nordic has refocused its strategy to emphasize therapeutic HIV vaccines, Chief Scientific Officer Paul Chaplin says.In 2007, the company reported that its MVA vaccine encoding the HIV nef gene controlled viral replication in a Phase II trial.With the idea that one gene was good and more might be better, the company has begun a Phase I/II trial of an MVA-multiantigen vaccine that encodes eight of the nine HIV genes.

    MVA vectors don't seem to present the same problems as adenovirus vectors, Chaplin says, and they can generate strong immune responses without replication.Developers don't want to use replicating vectors for therapeutic applications and risk adverse events in immunocompromised patients, he explains.

    COMPARED WITH tests of a preventive vaccine, those for a therapeutic one will quickly show any effectiveness on HIV replication in infected people, Chaplin explains.Although Bavarian Nordic worked with HVTN on earlier candidates, it now is conducting trials on its own.It might look for support again for larger trials, Chaplin says."But it is much easier to get funding after you've gotten proof of concept in the clinic," he adds.

    Both GeoVax and Bavarian Nordic are eager to advance their candidates."It's debatable how valuable the animal models truly are, since some people have had very promising animal data but very poor clinical data," Chaplin says.

  • View Online Source
    www.presscontacts.com/newsint____254449.aspx - [Cached Version]
    Last Visited: 4/1/2008  

    - Paul Chaplin, EVP Research & Development

  • View Online Source
    Bavarian Nordic - [Cached Version]
    Published on: 10/30/2001    Last Visited: 3/8/2005  

    Paul Chaplin, PhD, is named Vice President R&D and Chief Scientific Officer (CSO) of Bavarian Nordic.Paul Chaplin has for the last two years been Director of Immunology at Bavarian Nordic.As CSO Paul Chaplin will have overall responsibility for Bavarian Nordic's vaccine projects.

    Paul Chaplin will become a member of the Corporate Management of Bavarian Nordic.Corporate Management hereafter consists of Peter Wulff, President & CEO, Bo Sandroos, CFO, and Paul Chaplin, CSO.

  • View Online Source
    Bavarian Nordic - [Cached Version]
    Published on: 10/30/2001    Last Visited: 1/16/2005  

    Paul Chaplin, PhD, is named Vice President R&D and Chief Scientific Officer (CSO) of Bavarian Nordic.Paul Chaplin has for the last two years been Director of Immunology at Bavarian Nordic.As CSO Paul Chaplin will have overall responsibility for Bavarian Nordicâ€s vaccine projects.

    Paul Chaplin will become a member of the Corporate Management of Bavarian Nordic.Corporate Management hereafter consists of Peter Wulff, President & CEO, Bo Sandroos, CFO, and Paul Chaplin, CSO.

  • View Online Source
    Bavarian Nordic A/S - [Cached Version]
    Published on: 4/1/2002    Last Visited: 12/2/2002  

    CSO, VP of R&D: Dr. Paul Chaplin

  • View Online Source
    DKSH Australia - [Cached Version]
    Published on: 3/8/2005    Last Visited: 10/23/2006  

    Paul Chaplin: Chief Executive Officer

  • View Online Source
    EBR Index of Content - [Cached Version]
    Published on: 1/1/2001    Last Visited: 4/21/2007  

    As governments around the globe are acknowledging the need to be able to deal quickly with bioterrorist attacks, Paul Chaplin, Chief Scientific Officer and Vice President of Research and Development at Bavarian Nordic, considers Smallpox - Preventing the Unthinkable

  • View Online Source
    InternationalReports.net : Denmark 2006 - [Cached Version]
    Published on: 1/1/2006    Last Visited: 8/24/2006  

    "While our clinical focus has been to test the safety of IMVAMUNE® in immune-compromised groups because they cannot safely be given the existing smallpox vaccine, we expect the data we have generated to be applicable to the population at-large," explained Paul Chaplin, Executive Vice President, Research & Development.

  • View Online Source
    New Zealand Antarctic Heritage Trust: preservation of... - [Cached Version]
    Published on: 2/27/1999    Last Visited: 5/19/2006  

    Paul Chaplin - Executive Officer

  • View Online Source
    Phacilitate Advisory Boards - [Cached Version]
    Published on: 2/11/2009    Last Visited: 2/11/2009  

    Dr Paul Chaplin, Bavarian Nordic A/S

Page:  1 2 Next

Wrong Person?

Try these instead
Related searches
More...

Copyright © 2009 Zoom Information Inc. All rights reserved.

BBeachHead-2009-09-28_RC001.1 OM13